Compare Natera Inc. Common Stock (NTRA) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Toyota Motor Corp — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Toyota Motor Corp trades at $191 (market cap $221.69B). The key difference: Toyota Motor Corp is far larger — about 3.9× Natera Inc. Common Stock's market cap, and Toyota Motor Corp pays a 3.32% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Toyota Motor Corp for 116 Days on average.
| NTRA | TM | |
|---|---|---|
Market Cap | $57.03B | $221.69B |
Volume | 1,131,157 | 298,766 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $248.29 |
52-Week Low | $179.42 | $166.50 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $56.18B | $414.72B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Toyota Motor trades at $188.60, up 2.1% with bearish technical signals but strong fundamentals. The stock shows attractive valuation with P/E of 8.5 and P/S of 0.74, supported by consistent earnings beats. Recent news highlights growing U.S. market share and electrification progress, though China sales remain a concern. Cash flow trends show recovery from 2025's negative position to projected $2.25T positive in 2026.
Toyota presents a value opportunity with solid profitability and market positioning, though technical weakness and China headwinds warrant caution. The 37.5% buy rating from analysts reflects divided sentiment despite strong fundamentals. Key catalysts include electrification expansion and U.S. market gains, while risks involve production disruptions and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
